Parkinson's disease

• 1. Introduction

  ›

  Parkinson's disease has been with humanity far longer than its name suggests. A Nineteenth Dynasty Egyptian papyrus, the ancient ayurvedic text Charaka Samhita, and even a passage in Ecclesiastes 12:3 all contain what researchers believe are incomplete descriptions of its signature tremors and stiffness. Yet it took until 1817 for anyone to describe the disease as a unified neurological syndrome. That year, English physician James Parkinson published An Essay on the Shaking Palsy, drawing on six clinical cases - three of them people he had simply observed walking the streets near Hoxton Square in London. What made those strangers stand out? What was happening inside their bodies? And why, more than two centuries later, does the condition Parkinson named remain incurable, still spreading, and now ranked as the fastest-growing neurodegenerative disease on earth?

• 2. A Disease With Two Faces

  ›

  Tremor is the symptom most people associate with Parkinson's disease, and it does appear in roughly 70-75% of those who have it. The classic form is a resting tremor of the thumb and index finger moving in a circular motion at 4-6 Hz - a pattern clinicians call "pill-rolling". But the disease wears a second face that is often invisible to bystanders. Neuropsychiatric symptoms including anxiety, apathy, depression, hallucinations, and impulse control disorders occur in up to 60% of people with Parkinson's. These problems can appear before any shaking begins, arising during the prodromal phase when diagnosis is not yet clinically possible. A large systematic review found that non-motor symptoms such as depression and fatigue may actually contribute more to reduced quality of life than the motor symptoms do. Sleep disorders are particularly widespread, affecting up to 98% of people with Parkinson's; REM sleep behavior disorder, in which people physically act out their dreams, can precede the first motor symptom by years. Sensory deficits turn up in up to 90% of cases, and the disease is even linked to distinct skin conditions, including seborrheic dermatitis, which can appear as a premotor feature before the nervous system changes become detectable.

• 3. Inside the Damaged Brain

  ›

  By the time someone first notices a tremor, 50-80% of all dopamine-producing neurons in a brain region called the substantia nigra pars compacta have already degenerated. That loss is catastrophic, because dopamine is central to the circuits that control movement in the basal ganglia. The immediate cause of that neuronal death involves a protein called alpha-synuclein. Normally found at the tips of neurons, helping to release neurotransmitters, alpha-synuclein can misfold and clump together into structures called Lewy bodies and Lewy neurites. Once those aggregates form, they trigger the brain's own immune cells - the microglia - to release pro-inflammatory molecules. That protective response turns destructive when it becomes chronic, driving neuroinflammation that opens the blood-brain barrier to dangerous substances and increases oxidative stress. Mitochondrial dysfunction compounds the damage further, and the whole system feeds back on itself: impaired mitochondria lead to more alpha-synuclein accumulation, which causes more inflammation, which damages more cells. Three major cellular pathways - vesicular trafficking, lysosomal degradation, and mitochondrial maintenance - are all implicated in this cascade, and high-risk gene variants impair all three.

• 4. Genetics, Environment, and the PD Belt

  ›

  About 5-10% of Parkinson's cases are familial, tracing to specific inherited gene variants. LRRK2 is the most common autosomal dominant variant, responsible for 1-2% of all cases and as many as 40% of familial ones. Parkin variants are linked to nearly half of recessive, early-onset cases. Among Arab-Berber and Ashkenazi Jewish populations, rates of monogenic Parkinson's reach up to 40% and 20% respectively. But the other 90% of cases have no clearly identifiable genetic cause, and researchers increasingly look to the environment to explain why. Certain pesticides and herbicides - paraquat, glyphosate, and rotenone among them - are considered the most established environmental triggers. Paraquat is structurally similar to a compound called MPTP, which selectively kills dopaminergic neurons by disabling mitochondrial complex 1; it is now widely used in research to model the disease. Within the United States, high rates of Parkinson's cluster in the Midwest, the South, and agricultural regions elsewhere - a geography researchers have labeled the "PD belt" - and the association with rural residence is thought to be driven partly by herbicide and pesticide exposure. Traumatic brain injury and Type 2 diabetes are also recognized risk factors, while regular exercise, coffee, and diets rich in fruits, vegetables, whole grains, and fish are associated with lower risk.

• 5. The Long Road to Treatment

  ›

  Surgery for Parkinson's disease appeared in the 19th century, and by the 1960s it had evolved into procedures that destroyed tissue in the basal ganglia, thalamus, or globus pallidus. Then levodopa arrived. Although the compound was first synthesized by Casimir Funk in 1911, it did not enter clinical use until 1967. Once it did, surgical approaches largely disappeared, because levodopa - the immediate precursor to dopamine in the brain - offered relief that ablation could not match. Researchers who uncovered the dopamine connection included Arvid Carlsson and Oleh Hornykiewicz, working in the 1950s. Levodopa's own story is complicated: its metabolism outside the brain causes nausea and vomiting, so it is typically taken alongside inhibitors such as carbidopa, entacapone, or benserazide. Long-term use can also produce dyskinesia and motor fluctuations. Physicians have sometimes delayed prescribing it for that reason, though earlier administration is now known to improve motor function and quality of life. When medications fail, deep brain stimulation - developed by Alim Louis Benabid and colleagues in Grenoble, France, in the late 1980s - offers another option, implanting electrodes that deliver electrical impulses to the subthalamic nucleus or globus pallidus interna. Rehabilitation plays a complementary role: long-term physiotherapy lasting more than six months has been shown to reduce the need for antiparkinsonian medication, and the Lee Silverman voice treatment specifically targets the hypophonic, soft speech that affects most people with Parkinson's.

• 6. A Growing Global Burden

  ›

  As of 2024, Parkinson's disease is the second-most common neurodegenerative disease and the fastest growing in total cases worldwide. Global prevalence as of 2023 was estimated at 1.51 per 1000 people. Men are roughly 1.5 times more likely to be diagnosed than women. Between 1990 and 2016, cases increased by 74%, and even after accounting for the aging of the global population, prevalence rates still rose by 21.7%. The number of people living with the disease is projected to exceed 12 million by 2040, with China expected to carry nearly half of the global burden by 2030. The economic weight of that scale is already visible. In 2010, the total cost across Europe was estimated at 13.9 billion euros. In the United States, the figure was estimated at $51.9 billion in 2017 and is projected to surpass $79 billion by 2037. Family caregivers - often spouses - dedicate around 22 hours per week to care. The 2017 Parkinson's Progression Markers Initiative study identified three subtypes of the disease by severity: mild-motor predominant, with a mean survival of 20.2 years after diagnosis; intermediate, at 13.1 years; and diffuse malignant, at 8.1 years. Misdiagnosis remains common, with an error rate near 25%.

• 7. Public Faces and Future Research

  ›

  Actor Michael J. Fox was diagnosed with Parkinson's disease at 29. He has appeared without medication in television roles and before the United States Congress to illustrate the disease's effects. The Michael J. Fox Foundation, which he founded in 2000, has raised over $2 billion for Parkinson's research. Boxer Muhammad Ali showed signs of the disease at 38 but was not diagnosed until he was 42; questions about whether his condition was Parkinson's disease or parkinsonism related to boxing have never been fully resolved. Musician Ozzy Osbourne was also diagnosed with Parkinson's; he performed a farewell reunion concert with Black Sabbath on the 5th of July 2025, weeks before his death. The event raised over $190 million, some of which went toward Parkinson's research. On the scientific front, gene therapy trials are under way to deliver functional genetic material to dopaminergic neurons via viral vectors. Fecal microbiota transplants are being investigated, based on evidence that the gut microbiome is disrupted in Parkinson's and may produce toxic compounds. Dopaminergic neuron transplants derived from induced pluripotent stem cells have been tested in clinical trials, though results remain highly variable. The birthday of James Parkinson, the 11th of April, is now observed as World Parkinson's Day - a date that marks how far the science has come since those first six clinical observations near Hoxton Square, and how far it still has to go.